The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Assessing ISM6331, an AI-designed pan-TEAD inhibitor, in advanced solid tumors
Valentina Boni, MD, PhD, Universitary Hospital Quirónsalud Madrid, Madrid, Spain, discusses the potential of a ISM6331, a pan-TEAD inhibitor, discovered using an AI platform, which targets a hypoxia pathway and shows promising activity in mesothelioma, a hard-to-treat disease. This concept, assessed in a Phase I trial, NCT06566079, represents a proof of concept for the use of AI in developing new drugs that can inhibit novel pathways. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
